# EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial

> **NCT06897488** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 300 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **RADIATION:** Adjuvant Radiotherapy

## Key facts

- **NCT ID:** NCT06897488
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-17
- **Primary completion:** 2028-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06897488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06897488, "EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06897488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*